Cipla Ltd. — Board/Management Information 2022

Jul 29, 2022

29th July 2022

(1) BSE Limited Listing Department, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai 400 001

Scrip Code: 500087

• (3) SOCIETE DE LA BOURSE DE LUXEMBOURG Societe Anonyme 35A Boulevard Joseph 11, L-1840 Luxembourg
• (2) National Stock Exchange of India Limited Listing Department Exchange Plaza, 5th floor, Plot no. C/1, G Block, Bandra Kurla Complex, Bandra (East), Mumbai - 400 051 Scrip Code: CIPLA EQ

Sub: Appointment of Dr. Mandar Purushottam Vaidya as an Independent Director

Dear Sir/ Madam,

In compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations'), we hereby notify that on the recommendation of the Nomination and Remuneration Committee and subject to the approval of the shareholders at the ensuing Annual General Meeting, the Board of the Directors at its meeting held today i.e., on 29th July 2022, has appointed Dr. Mandar Purushottam Vaidya (DIN: 09690327) as an additional and independent director of the Company for p period of 5 years with effect from 29th July 2022 to 28th July 2027 (both days inclusive).

The details as required under the SEBI Listing Regulations read with the SEBI Circular No. CIR/CFD/ CMD/ 4/ 2015 dated 9th September 2015 are given in Annexure A to this letter.

Kindly take the above information on record .

Thanking you,

Yours faithfully,

Company Secretary

Encl: As above Prepared by: Chirag Hotchandani

Cipla Ltd.

Cipla

Annexure A

DIN	09690327
Name of Director	Dr. Mandar Purushottam Vaidya
Reason for change viz. appointment,FesigRatieR,reme¥al,deatl=IeFetl=lerwise	Appointment of Dr. Mandar Purushottam Vaidya, as additional and anindependent director of the Company for a period of 5 years w.e.f.29th July 2022 to 28th July 2027 (both days inclusive)
Date of appointment / GessatieR (asapplicable) & term of appointment	For period of 5 year commencing from 29th July 2022 to 28th July 2027
Brief Profile	Dr. Mandar Vaidya is a medical doctor and a management graduatefrom the Jamnalal Bajaj Institute of Management Studies, India.
	He spent 15 years at McKinsey (2002-2017), the last seven as a partnerwhere he co-led the healthcare practice in India and established thehospitals practice for Asia. He has served leading pharmaceuticalcompanies in India and globally, across several areas such as corestrategy, manufacturing productivity improvement, R&D productivity,portfolio management, M&A and procurement programs.
	From 2017 to 2019, he worked part time, advising several healthcarecompanies, providing leadership coaching and designing and teachinga course on problem solving at Ashoka University.
	In August 2019, he joined OYO, a global travel-tech company as CEO -SE Asia & Middle East, driving growth, doubling the number of-hotelsand homes, while transforming the regions contribution margin to a netpositive territory. He led the business through the COVID crisis,improving EBIDTA loss to a negligible level while managing massivebusiness disruptions.
	ISince March 2021 he is the CEO - OYO Vacation Homes (OVH), Europe,a strategically important core market for the company. OVH ·is Europe'ssecond largest vacation homes company. He leads three acquiredbrands, DanCenter, Belvilla and Traum FW, each with a multi decadelegacy. He has turbo charged their growth and profitability by migratingthemintoatechforwardenvironmentwhileretainingtheuniqueness of each business built over the last several decades.
Disclosure of relationships betweendirectors (in case of appointment ofa director).	None
Information as required pursuant toCircular with ref.no.LIST/BSE14/COMP/2018-19andtheNational Stock Exchange of India Ltdwith ref. no. NSE/ CML/ 2018/24,dated 20th June 2018	Dr. Mandar Vaidya is not debarred from holding the office of directorby virtue of any SEBI order or any other such authority.